ClinicalTrials.gg
RecruitingNCT07720739Updated Jul 22, 2026

Efficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy

An interventional study of Intrathecal Morphine and Erector Spinae Plane Block in Postoperative Pain and Midline Laparotomy, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies testing morphine in Pain, Postoperative — 18 open to participants now, 21 under way, 1 of them phase 3. Morphine · Pain, Postoperative.

Planned enrollment
59th of 97
75 · median 90
Started
2026
with 5 others
No phase
34 of 97
10 open now
Primary completion
2026-11
later than 11 of 20 live
Registered
92nd of 97
by date
Lead sponsor
3 of 97
Sohag University

Among the 97 studies testing morphine in Pain, Postoperative, this one is the 59th largest by planned enrollment, is one of 6 that started in 2026, is one of 34 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 92nd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 97 studies testing morphine in Pain, Postoperative are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About morphine

Morphine: first FDA approval 1984 (DURAMORPH PF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing morphine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study evaluates whether combining two distinct pain-relief techniques-a peripheral nerve block called the Erector Spinae Plane Block (ESPB) and a low-dose spinal medication injection called Intrathecal Morphine (ITM)-provides better postoperative pain management for adult patients undergoing major midline abdominal surgery (laparotomy) compared to using either technique alone. The main goal is to see if this combination improves pain control and reduces the total amount of opioids required by patients within the first 48 hours after surgery.

03

Conditions studied

  • Postoperative Pain
  • Midline Laparotomy

Browse trials for

Keywords

  • Erector Spinae Plane Block
  • Intrathecal morphine
  • Opioid-sparing
  • Abdominal surgery
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Patients scheduled to undergo elective or emergency midline exploratory laparotomy.

(ASA) physical status I, II, or III. Intact cognitive ability to comprehend study procedures, use the Numeric Rating Scale (NRS) accurately, and provide .

Exclusion Criteria to regional or neuraxial anesthesia (e.g., patient refusal, localized infection at needle insertion sites, known coagulopathy ( >1.5 or count \<80,000/\mu L), or un-pausable therapeutic anticoagulation).

Known allergy or severe to local anesthetics or morphine. Chronic pain conditions requiring daily opioid consumption for >3 months preoperatively.

Documented history of substance use disorder. Severe chronic respiratory disease (e.g., requiring home oxygen therapy, or severe obstructive sleep apnea not managed with CPAP).

Neurological or psychiatric conditions that compromise sensory perception or communication.

Surgical incisions planned to extend significantly past the midline. Severe spinal deformities or a history of spinal surgery at the targeted block/injection interspaces.

Concurrent enrollment in any other interventional clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Intrathecal morphine alone

    Drug: Intrathecal Morphine (ITM) Under sterile conditions preoperatively, a 25-gauge spinal needle is introduced at the L3-L4 or L2-L3 interspace. A 1.0 mL solution containing 100 µg of preservative-free morphine (diluted with 0.9% normal saline) is injected intrathecally upon free CSF flow. No ESPB is performed.

    Drug: Intrathecal Morphine

  • Active comparator
    Bilateral Erector Spinae Plane Block

    Procedure: Bilateral Erector Spinae Plane Block Preoperatively, using a high-frequency linear ultrasound probe at the T8 vertebral level, an echogenic needle is inserted in-plane deep to the erector spinae muscle and superficial to the transverse process. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine is injected. The procedure is repeated on the opposite side. No ITM is performed.

    Procedure: Erector Spinae Plane Block

  • Experimental
    Intrathecal morphine + Bilateral Erector Spinae Plane Block

    Combination Regimen Patients receive both interventions preoperatively. The bilateral T8 ESPB (20 mL 0.25% bupivacaine per side) is performed first in the lateral decubitus position, followed immediately by the lumbar L2-L3 or L3-L4 ITM injection (100 mcg preservative-free morphine).

    Drug: Intrathecal Morphine · Procedure: Erector Spinae Plane Block

Interventions

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of a single-shot intrathecal injection containing hyperbaric bupivacaine combined with preservative-free morphine (ITM) during spinal anesthesia prior to the surgical incision."

    Also known as: ITM, Spinal Morphine

  • ProcedureErector Spinae Plane Block

    Bilateral ultrasound-guided erector spinae plane block performed at the T8-T10 level using a local anesthetic solution (such as bupivacaine or ropivacaine) injected deep to the erector spinae muscle fascia for postoperative abdominal analgesia.

    Also known as: ESBP, Ultrasound-guided ESPB

06

What researchers measure

Primary outcomes

  1. Time to First Rescue Analgesia

    Duration of time (in minutes/hours) elapsed from PACU admission to the patient's first request for an IV morphine rescue bolus.

    Time frame: Up to 48 hours postoperatively.

  2. Postoperative Pain Intensity

    Numeric Rating Scale (NRS) score ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: At rest and during a standardized cough at 0, 2, 4, 6, 12, 24, and 48 hours postoperatively.

  3. Cumulative Opioid Consumption

    Total postoperative intravenous rescue morphine consumed, calculated and recorded in Morphine Milligram Equivalents (MME).

    Time frame: Up to 48 hours postoperatively.

Secondary outcomes

  1. Time to First Ambulation

    Time taken (in hours) from the end of surgery until the patient is able to walk more than 5 meters with assistance.

    Time frame: Up to hospital discharge (typically up to 7 days).

  2. Time to Readiness for PACU Discharge

    Time in minutes from PACU admission until the patient achieves a modified Aldrete score \\ge9.

    Time frame: Within the first 24 hours postoperatively.

  3. Incidence of Adverse Events

    Presence or absence (percentages) of respiratory depression (RR \<8/min or SpO\_2 \<90% on room air), PONV requiring treatment, or pruritus requiring treatment.

    Time frame: Up to 48 hours postoperatively.

  4. Patient Satisfaction with Pain Management

    Score on a 5-point Likert scale ranging from 1 (Dissatisfied) to 5 (Very Satisfied).

    Time frame: Assessed at 48 hours postoperatively.

  5. Quality of Recovery

    Total score obtained from the 9-item Quality of Recovery (QoR-9) questionnaire.

    Time frame: Postoperative Day 1 (approximately 24 hours).

  6. Healthcare Utilization

    Total length of hospital stay measured in days.

    Time frame: From day of surgery to hospital discharge (up to 30 days).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Beverly A, Kaye AD, Ljungqvist O, Urman RD. Essential Elements of Multimodal Analgesia in Enhanced Recovery After Surgery (ERAS) Guidelines. Anesthesiol Clin. 2017 Jun;35(2):e115-e143. doi: 10.1016/j.anclin.2017.01.018. PubMed 28526156 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the research team to protect patient privacy, maintain strict data confidentiality regarding clinical interventions, and comply with institutional data management policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Nov 2026, 4 months later.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Jul 22, 2026
StartEst.
Jul 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07720739
Lead sponsor
Sohag University
Responsible party
Ahmed Samir Abdelmonaem (Resident of Anesthesia, Surgical Intensive Care and Pain management, Sohag University) — Principal investigator
First posted
Jul 22, 2026
Start date
Jul 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion